title: Current status of high dose chemotherapy in breast cancer.
abstract: To date, no definite answers are available to the initial question, whether or not HDCT and ASCT can improve quantity or quality of life. Completing the available prospective, randomized phase III studies; using HDCT earlier in the course of treatment; applying drugs that are active breast cancer; comparing the experimental treatment to standard therapy; and using appropriate sample size to detect clinically meaningful and statistically significant differences are all paramount requirements to answer the question successfully. Within the next few years, a number of European [13] and two Canadian Studies [6, 14] that are currently accruing patients, will contribute versus important information regarding the role of HDCT and ABMT for breast cancer.
authors.affiliation: Dept. Oncology, Faculty of Medicine, University of Calgary, Tom Baker Cancer Centre, Canada. gluck@ucalgary.ca
authors.forename: S
authors.initials: S
authors.lastname: Glück
authors.forename: D
authors.initials: D
authors.lastname: Stewart
mesh_terms: D001943:Breast Neoplasms / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans